<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35285546</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1540-8191</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cardiac surgery</Title>
          <ISOAbbreviation>J Card Surg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Unrecognized indication for aortic valve neocuspidization: Patient with warfarin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.</ArticleTitle>
        <Pagination>
          <StartPage>1733</StartPage>
          <EndPage>1735</EndPage>
          <MedlinePgn>1733-1735</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.16404</ELocationID>
        <Abstract>
          <AbstractText>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe disorders, characterized by necrosis and epidermal detachment. Most important known acquired etiological factor is medications. Warfarin is one of the most common medications of cardiac valve surgery, which may rarely cause SJS or TEN. From this perspective, Aortic Valve Neocuspidization (AVNeo) procedure may be a good treatment option for such kind of patients, with a unique advantage of anticoagulation free postoperative course. In this report we aimed to share a patient with warfarin-induced STS/TEN, who was successfully treated with AVNeo procedure and mitral valve replacement.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Karabacak</LastName>
            <ForeName>Kubilay</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-6290-1571</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kadan</LastName>
            <ForeName>Murat</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Demirkıran</LastName>
            <ForeName>Tuna</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yaşar</LastName>
            <ForeName>Ayşe Saatçi</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>İnce</LastName>
            <ForeName>Mehmet Emin</ForeName>
            <Initials>ME</Initials>
            <Identifier Source="ORCID">0000-0002-6803-5192</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Reanimation, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bolcal</LastName>
            <ForeName>Cengiz</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Card Surg</MedlineTA>
        <NlmUniqueID>8908809</NlmUniqueID>
        <ISSNLinking>0886-0440</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013262" MajorTopicYN="Y">Stevens-Johnson Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Stevens-Johnson syndrome</Keyword>
        <Keyword MajorTopicYN="N">aortic valve neocuspidization</Keyword>
        <Keyword MajorTopicYN="N">toxic epidermal necrolysis</Keyword>
        <Keyword MajorTopicYN="N">warfarin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35285546</ArticleId>
        <ArticleId IdType="doi">10.1111/jocs.16404</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Stern RS, Divito SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done. J Invest Dermatol. 2017;137(5):1004-1008.</Citation>
        </Reference>
        <Reference>
          <Citation>Karabacak K, Kubat E, Erol G, et al. Aortic neocuspidization with autologous pericardium: initial experience of single center. World J Cardiovasc Surg. 2021;11(6):51-60.</Citation>
        </Reference>
        <Reference>
          <Citation>Ozaki S, Kawase I, Yamashita H, Uchida S, Takatoh M, Kiyohara N. Midterm outcomes after aortic valve neocuspidization with glutaraldehyde-treated autologous pericardium. J Thorac Cardiovasc Surg. 2018;155(6):2379-2387.</Citation>
        </Reference>
        <Reference>
          <Citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-1607.</Citation>
        </Reference>
        <Reference>
          <Citation>Kuroda T, Yokoyama Y, Yamada M, Yuhara S, Hasegawa H, Yokote J. Warfarin-induced toxic epidermal necrolysis after mitral valve replacement. Asian Cardiovasc Thorac Ann. 2020;28(9):601-603.</Citation>
        </Reference>
        <Reference>
          <Citation>Xiong H, Liu T, Xiao J, et al. Warfarin-induced Stevens-Johnson syndrome with severe liver injury. J Int Med Res. 2021;49(7):1-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart. 2006;92(8):1022-1029.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
